Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Neutec Group
The Turkish pharmaceutical market reached $5.6bn in 2017. Despite strong competition from multinationals, Abdi Ibrahim, a local company, was market leader last year with a turnover of $380m. It was followed by Novartis and Pfizer.
Takeda tantalizingly disclosed during its third quarter results that it has set aside funds for an acquisition worth around $450m in an undisclosed emerging market. What are the likely targets?
TUBITAK (The Scientific and Technological Research Council of Turkey) will produce biosimilars with Nobel Ilac, MSD provides pembrolizumab free to 25 patients in Turkey, Abdi Ibrahim intensifies its R&D efforts, and Takeda purchases a portfolio of new products.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2015.
- Generic Drugs
- Other Names / Subsidiaries
- Takeda Pharmaceutical Company Limited
- Neutec Ilac Sanayi Ve Ticaret AS
- Neutec Inhale
- Neutec Cef
- Neutec Solid
- Neutec R&D
- Neutec Ilaç Sanayi ve Ticaret A.S.
- Neutec Pharma Group